Aurobindo Pharma Ltd reported a 92 per cent jump in consolidated net profit to Rs 198.32 crore in the quarter ended September 30, compared with Rs 103.19 crore in the same period of 2009-10. Net sales were up 26 per cent to touch Rs 1,112.62 crore from Rs 882.64 crore in the previous comparable period.
The company has declared an interim dividend of 100 per cent, ie, Rs 5 per share of Rs 5 face value. Its board also approved stock split with each share of Rs 5 face value split into five equity shares of Rs1 face value, according to a release.
PV Ramprasad Reddy, chairman, Aurobindo Pharma, said satisfactory progress in business resulted in improved performance during the quarter. He expects the company's recent commercialisation of large formulations units in Jadcherla special economic zone in Andhra Pradesh and New Jersey to further strengthen the operations, going forward.
The company’s revenues come from three streams -- formulations, active ingredients, and dossier licensing and supply arrangement.
At Rs 615.7 crore, formulation sales constituted 57.7 per cent of gross sales and were up 38.3 per cent in the said quarter. It reported five ANDAs (abbreviated new drug applications) in the US in the three months to September and 33 dossier filings in Europe.
Active ingredients business contributed Rs 451.7 crore, or 40.6 per cent, to the total operating income, while dossier income was Rs 69.9 crore (6.2 percent).
In the formulations segment, the US alone accounts for a 48 per cent share, followed by anti-retro virals at 28 per cent and European market at 14 per cent.
The company filed for three drug master files (DMF) in the US, 48 formulations dossiers and 80 APIs (active pharmaceutical ingredients) DMF in other regulated markets, and 13 patents in the said quarter. It commercialised 67 products in the US market during the quarter.
On a standalone basis, exports accounted for 72.3 per cent while domestic sales 27.7 per cent to the second quarter revenue.
